155 related articles for article (PubMed ID: 28076247)
1. 5-Day versus 10-Day Course of Fluoroquinolones in Outpatient Males with a Urinary Tract Infection (UTI).
Mospan GA; Wargo KA
J Am Board Fam Med; 2016 Nov; 29(6):654-662. PubMed ID: 28076247
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis.
Peterson J; Kaul S; Khashab M; Fisher AC; Kahn JB
Urology; 2008 Jan; 71(1):17-22. PubMed ID: 18242357
[TBL] [Abstract][Full Text] [Related]
3. A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis.
Klausner HA; Brown P; Peterson J; Kaul S; Khashab M; Fisher AC; Kahn JB
Curr Med Res Opin; 2007 Nov; 23(11):2637-45. PubMed ID: 17880755
[TBL] [Abstract][Full Text] [Related]
4. A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis.
Connolly LE; Riddle V; Cebrik D; Armstrong ES; Miller LG
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378708
[TBL] [Abstract][Full Text] [Related]
5. Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. Sparfloxacin Multicenter Uncomplicated Urinary Tract Infection Study Group.
Henry DC; Nenad RC; Iravani A; Tice AD; Mansfield DL; Magner DJ; Dorr MB; Talbot GH
Clin Ther; 1999 Jun; 21(6):966-81. PubMed ID: 10440621
[TBL] [Abstract][Full Text] [Related]
6. Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST).
Ten Doesschate T; van Mens SP; van Nieuwkoop C; Geerlings SE; Hoepelman AIM; Bonten MJM
BMC Infect Dis; 2018 Dec; 18(1):626. PubMed ID: 30518334
[TBL] [Abstract][Full Text] [Related]
7. Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections.
Wagenlehner F; Nowicki M; Bentley C; Lückermann M; Wohlert S; Fischer C; Vente A; Naber K; Dalhoff A
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29339395
[TBL] [Abstract][Full Text] [Related]
8. Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections.
Naber KG; Allin DM; Clarysse L; Haworth DA; James IG; Raini C; Schneider H; Wall A; Weitz P; Hopkins G; Ankel-Fuchs D
Int J Antimicrob Agents; 2004 Jun; 23(6):596-605. PubMed ID: 15194131
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections.
Armstrong ES; Mikulca JA; Cloutier DJ; Bliss CA; Steenbergen JN
BMC Infect Dis; 2016 Nov; 16(1):710. PubMed ID: 27887579
[TBL] [Abstract][Full Text] [Related]
10. A randomized, active-controlled, multicentre clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus levofloxacin in Chinese adults with acute uncomplicated or complicated urinary tract infection.
Li Y; Yin Y; Peng X; Zheng H; Fu F; Liu Z; Wu X; Wu X; Zheng S; Chen N; He L; Ren L; Ni Z; Li D; Liang P; Lv X; Zhang Y
Ann Med; 2021 Dec; 53(1):217-226. PubMed ID: 33331182
[TBL] [Abstract][Full Text] [Related]
11. Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial.
Ren H; Li X; Ni ZH; Niu JY; Cao B; Xu J; Cheng H; Tu XW; Ren AM; Hu Y; Xing CY; Liu YH; Li YF; Cen J; Zhou R; Xu XD; Qiu XH; Chen N
Int Urol Nephrol; 2017 Mar; 49(3):499-507. PubMed ID: 28108978
[TBL] [Abstract][Full Text] [Related]
12. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).
Wagenlehner FM; Umeh O; Steenbergen J; Yuan G; Darouiche RO
Lancet; 2015 May; 385(9981):1949-56. PubMed ID: 25931244
[TBL] [Abstract][Full Text] [Related]
13. Resistance Patterns of Escherichia coli in Women with Uncomplicated Urinary Tract Infection Do Not Correlate with Emergency Department Antibiogram.
Hines MC; Al-Salamah T; Heil EL; Mallemat H; Witting MD; Johnson JK; Winters ME; Hayes BD
J Emerg Med; 2015 Dec; 49(6):998-1003. PubMed ID: 26281821
[TBL] [Abstract][Full Text] [Related]
14. Lomefloxacin versus ciprofloxacin in the treatment of complicated urinary tract infections: a multicenter study.
Pisani E; Bartoletti R; Trinchieri A; Rizzo M
J Chemother; 1996 Jun; 8(3):210-3. PubMed ID: 8808718
[TBL] [Abstract][Full Text] [Related]
15. A pilot study on prevention of catheter-related urinary tract infections with fluoroquinolones.
Esposito S; Noviello S; Leone S; Marvaso A; Drago L; Marchetti F;
J Chemother; 2006 Oct; 18(5):494-501. PubMed ID: 17127226
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for urinary tract infections due to ciprofloxacin-resistant Escherichia coli in a tertiary care urology department in Switzerland.
Nicoletti J; Kuster SP; Sulser T; Zbinden R; Ruef C; Ledergerber B; Weber R
Swiss Med Wkly; 2010; 140():w13059. PubMed ID: 20648400
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
Arslan H; Azap OK; Ergönül O; Timurkaynak F;
J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
[TBL] [Abstract][Full Text] [Related]
18. Optimal duration of antibiotic therapy for uncomplicated urinary tract infection in older women: a double-blind randomized controlled trial.
Vogel T; Verreault R; Gourdeau M; Morin M; Grenier-Gosselin L; Rochette L
CMAJ; 2004 Feb; 170(4):469-73. PubMed ID: 14970093
[TBL] [Abstract][Full Text] [Related]
19. Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections.
Naber KG; Bartnicki A; Bischoff W; Hanus M; Milutinovic S; van Belle F; Schönwald S; Weitz P; Ankel-Fuchs D
Int J Antimicrob Agents; 2004 Mar; 23 Suppl 1():S41-53. PubMed ID: 15037328
[TBL] [Abstract][Full Text] [Related]
20. Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections.
Carson C; Naber KG
Drugs; 2004; 64(12):1359-73. PubMed ID: 15200349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
